Safety Clearance for Down Syndrome Trial
Aelis Farma has cleared a critical regulatory hurdle. The biotechnology firm announced that its independent Data Monitoring Committee (IDMC) authorized the continuation of its Phase IIb clinical trial for AEF0217 without modifications. The drug is currently being tested as a treatment for cognitive deficits linked to Down syndrome, or trisomy 21.
Targeting Cognitive Impairment
The IDMC oversees the study of adolescents and adults over the age of 16. AEF0217 is designed to address specific cognitive impairments, including challenges with memory, language, reasoning, and attention. The drug operates based on the company’s research into the pregnenolone hormone, which plays a role in regulating brain activity. By targeting these specific pathways, Aelis Farma aims to provide a pharmacological intervention for cognitive deficits.
Science of the CB1 Receptor
Founded by Pier Vincenzo Piazza, a former researcher at Inserm, Aelis Farma focuses on its discovery of pregnenolone.
Market Recovery and Clinical Stakes
The company previously explored using its technology to treat the effects of excessive cannabis consumption, but that program faced a clinical setback in September 2024. Following the disclosure of those trial results, the company’s share price plunged by more than 90%. The recent positive recommendation from the IDMC regarding the trisomy 21 trial has served as a point of renewed interest for investors, contributing to a recovery in the company’s share price since the beginning of the year.
Trial Objectives and Scope
Aelis Farma’s development of AEF0217 targets the biological mechanisms that contribute to cognitive deficits.
- Target Population: Adolescents and adults (16+ years).
- Primary Objective: Improvement in cognitive functions, specifically learning, attention, and memory.
- Mechanism: Modulation of brain activity via the pregnenolone pathway.
While the current Phase IIb trial remains ongoing, the recommendation to continue without changes marks a milestone for the company’s clinical pipeline. Aelis Farma continues to monitor the study to gather data on whether AEF0217 can effectively improve cognitive outcomes for the Down syndrome community. Future updates will depend on the final analysis of the Phase IIb data once the study concludes.